登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 36 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 36
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
- 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
- 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
- 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
- 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
- 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心河南医药大学第一附属医院First Affiliated Hospital of Xinxiang Medical University新乡医院页面
- 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
- 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
- 研究中心江门市中心医院Jiangmen Central Hospital江门医院页面
- 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
- 研究中心LinYi Cancer Hospital临沂医院页面
- 研究中心南方医科大学南方医院Nanfang Hospital广州医院页面
- 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
- 研究中心江苏省苏北人民医院Northern Jiangsu People's Hospital扬州医院页面
- 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
- 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
- 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
- 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面
- 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
- 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
- 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
- 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07222566,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Have pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV)squamous or non-squamous NSCLC and not be a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer Tumor, lymph nodes, metastasis (TNM) staging system).
入选标准第 2 条
Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy
入选标准第 3 条
Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1.
排除标准第 5 条
Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC.
排除标准第 19 条
Prior radiotherapy > 30 Gy to the lung < 6 months of first dose of study intervention
排除标准第 21 条
Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy.
排除标准第 25 条
Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1
入选标准第 6 条
Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology.
排除标准第 1 条
Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
排除标准第 4 条
Grade ≥3 pulmonary disease unrelated to underlying malignancy
排除标准第 10 条
Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV).
排除标准第 15 条
Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.
排除标准第 32 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07222566,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
18 years of age or older at screening. Have pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV)squamous or non-squamous NSCLC and not be a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer Tumor, lymph nodes, metastasis (TNM) staging system). Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy PD-L1 status available based on local testing results Measurable disease based on RECIST v1.1 per investigator. Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1 Expected survival ≥12 weeks排除标准:Exclusion Criteria:
Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology. Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter < 1 cm are permitted. Participants with clinically significant risk of hemorrhage or fistula are excluded. Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1. Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody. History of allogeneic organ / hematopoietic stem cell transplantation. Participants with any of the following respiratory conditions: Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis Grade ≥3 pulmonary disease unrelated to underlying malignancy History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial/severe venous thromboembolic events. Major surgery < 4 weeks or minor surgery < 3 days prior to first dose of study intervention. History of severe bleeding tendency or coagulation dysfunction History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose. Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV). Participants with history of immunodeficiency Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study. Previous systemic anti-tumor therapy including: Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC. Previous treatment with immunotherapy Prior radiotherapy > 30 Gy to the lung < 6 months of first dose of study intervention Palliative local therapy < 2 weeks before the first dose of study intervention; Non-specific immunomodulatory therapy < 2 weeks before the first dose. Prior systemic anti-angiogenic therapy Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy. Prior and concomitant therapy: therapeutic oral or parenteral anticoagulants or thrombolytic agents < 10 days to the first dose. chronic antiplatelet therapy <7 days to randomization. live or attenuated live vaccine < 4 weeks to the first dose. current high-dose systemic corticosteroids. prohibited concomitant medication(s) < 21 days to the first dose. Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.
引自 ClinicalTrials.gov, NCT07222566, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07222566,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。